This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
TALOS-AMI was a randomized phase 4 parallel-group treatment trial evaluating two antiplatelet strategies in stabilized patients with acute myocardial infarction.
| Feature | TALOS-AMI |
|---|---|
| Condition | Acute Myocardial Infarction |
| Phase | Phase 4 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | The Catholic University of Korea |
| Enrollment | 2590 |
2. Clinical Question
The central question was whether two aspirin-based antiplatelet strategies could be compared in stabilized patients after acute myocardial infarction using a randomized clinical trial framework.
Population
Stabilized patients with acute myocardial infarction.
Intervention
Aspirin + Ticagrelor.
Comparator
Aspirin + Clopidogrel.
Primary question
What is the comparative cumulative incidence of the prespecified net adverse clinical event endpoint between 1 month and 12 months after acute myocardial infarction?
3. Trial Design
| Study arm | Intervention |
|---|---|
| Arm 1 | Aspirin + Ticagrelor |
| Arm 2 | Aspirin + Clopidogrel |
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Cumulative incidence of Net adverse clinical event | 1 month to 12months after AMI | Composite endpoint of MACCE (CV death, MI, or stroke) + BARC bleeding (type 2, 3 or 5) between 1 and 12 months after AMI |
5. Planned Analysis
The registry identifies the primary endpoint as a cumulative incidence composite endpoint measured between 1 month and 12 months after acute myocardial infarction.
For a time-to-event composite endpoint with competing clinical events, analysis commonly involves estimating event incidence over time and comparing groups using methods appropriate for the endpoint structure. The specific statistical analysis plan for this endpoint is not reported in the ClinicalTrials.gov record.
6. Statistical Methodology
Composite endpoints
The primary endpoint combines multiple clinical outcomes: MACCE components (CV death, MI, or stroke) and BARC bleeding events (type 2, 3 or 5). Composite endpoints are designed to evaluate an overall clinical outcome that includes several related events.
The interpretation depends on the relative contribution of each component. Components may differ in clinical importance, frequency, and treatment effect.
Cumulative incidence analysis
The registry defines the endpoint using cumulative incidence between specified follow-up times. Cumulative incidence describes the proportion of patients experiencing an event by a particular time point while accounting for the structure of follow-up.
Randomized comparison
Randomization is intended to balance measured and unmeasured baseline characteristics between treatment groups, allowing the treatment comparison to be interpreted as a randomized estimate rather than an observational association.
7. Statistical Methods Explained
Why use a composite endpoint?
A composite endpoint allows multiple clinically relevant outcomes to contribute to one overall measure. The statistical gain in event frequency must be balanced against differences among component events.
What does cumulative incidence measure?
Cumulative incidence estimates how frequently an event occurs over a defined period. It differs from simply counting events because it incorporates follow-up time.
Why is randomization important?
Random allocation reduces systematic differences between groups at the start of the study, supporting causal interpretation of observed treatment differences.
Why are bleeding and ischemic events combined?
The registry-defined primary endpoint combines MACCE and BARC bleeding events into a single net adverse clinical event measure. Interpretation requires understanding that the endpoint represents the combined occurrence of these categories.
Why does masking matter?
The registry reports masking as none. In unmasked trials, knowledge of assigned treatment can potentially influence behavior, reporting, or clinical management, depending on the endpoint.
What is the difference between a treatment effect and an endpoint definition?
The endpoint definition specifies what outcome is measured. The statistical comparison estimates whether event occurrence differs between randomized groups.
8. Limitations
- No posted numerical results: The ClinicalTrials.gov record does not report primary endpoint estimates, confidence intervals, or p-values.
- Composite endpoint interpretation: A composite measure combines events that may differ in frequency and clinical consequences.
- Open-label design: The registry reports masking as none, which can affect interpretation of outcomes influenced by clinical decisions or reporting.
- Endpoint-specific interpretation: The net adverse clinical event endpoint requires consideration of both ischemic and bleeding components.
- Analysis details: The registry does not report additional statistical details such as missing-data handling, multiplicity adjustment, or interim analyses.
9. Why This Trial Matters Statistically
TALOS-AMI is a useful example of several important concepts in clinical-trial statistics: randomized treatment comparison, composite endpoints, cardiovascular event definitions, and interpretation of net clinical outcomes.
| Concept | How it appears in TALOS-AMI |
|---|---|
| Randomization | Randomized allocation between two treatment strategies |
| Parallel design | Two-arm parallel treatment comparison |
| Composite endpoint | MACCE plus BARC bleeding events |
| Cumulative incidence | Primary endpoint measured from 1 month to 12 months after AMI |
| Clinical outcome balance | Combines ischemic and bleeding outcomes into one endpoint |
10. Sources
- ClinicalTrials.gov: NCT02018055.
- PubMed: Publication record.
- PubMed: Publication record.
- PubMed: Publication record.
- PubMed: Publication record.
Continue through the Clinical Biostats knowledge graph
Explore additional clinical trial methods, statistical tutorials, and analysis tools.
11. Record Summary
TALOS-AMI provides an example of a randomized clinical trial evaluating a composite net adverse clinical event endpoint in patients with acute myocardial infarction. The statistical framework centers on randomized comparison, cumulative incidence assessment, and careful interpretation of combined ischemic and bleeding outcomes.